Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Stock Information for Genelux Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Genelux Corporation

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.